Skip to main content

Table 4 Univariate and multivariate analysis of overall survival and progression-free survival – Chemo-naive group

From: Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience

Factors

Univariate analysis

Multivariate analysis

Progression-free survival

Overall survival

Progression-free survival

Overall survival

P value

HR

95 % CI

P value

HR

95 % CI

P value

HR

95 % CI

P value

HR

95 % CI

Time from ADT to CRPC (<10 vs ≥ 10 months)

0.0306

2.191

1.057–4.542

0.0002

4.566

1.913–10.898

0.816

1.104

0.49–2.489

0.0336

2.656

1.061–6.648

ECOG (2–3 vs 0–1)

0.273

1.51

0.718–3.176

0.0034

3.392

1.426–8.071

N.A.

N.A.

N.A.

0.0001

4.907

1.648–14.612

Age (<75 vs ≥75)

0.2687

0.664

0.319–1.381

0.8875

1.068

0.43–2.653

N.A.

N.A.

N.A.

N.A.

N.A.

N.A.

Gleason score ( ≥8 vs <8)

0.9539

1.023

0.471–2.225

0.9549

0.973

0.376–2.515

N.A.

N.A.

N.A.

N.A.

N.A.

N.A.

Visceral met (yes vs no)

0.0088

4.7

1.313–16.82

0.0007

6.907

1.881–25.357

0.0126

5.891

1.43–24.267

0.0015

4.8

1.026–22.465

Symptomatic (yes vs no)

0.6554

1.183

0.565–2.476

0.1193

1.966

0.826–4.682

N.A.

N.A.

N.A.

N.A.

N.A.

N.A.

PSA doubling time (<2 months vs ≥2 months)

0.1667

1.651

0.804–3.393

0.4794

1.573

0.568–3.319

N.A.

N.A.

N.A.

N.A.

N.A.

N.A.

Baseline PSA ( ≥200 vs <200 ug/l )

0.0014

3.26

1.513–7.021

0.0365

2.558

1.028–6.364

0.0686

2.15

0.933–4.954

0.6339

1.313

0.428–4.038

Baseline ALP ( ≥120 vs <120 IU/l)

0.1464

1.69

0.825–3.466

0.0535

2.459

0.987–6.13

N.A.

N.A.

N.A.

N.A.

N.A.

N.A.

Baseline Hb (<12 vs ≥12 g/dl)

0.1618

1.676

0.805–3.488

0.023

2.712

1.109–6.631

N.A.

N.A.

N.A.

0.0409

2.696

0.912–7.7971

PSA response (yes vs no)

<0.0001

0.135

0.061–0.299

0.0001

0.176

0.067–0.459

<0.0001

0.186

0.079–0.439

0.0001

0.104

0.025–0.387

PSA flare (yes vs no)

0.0623

0.471

0.209–1.06

0.0652

0.373

0.125–1.111

N.A.

N.A.

N.A.

N.A.

N.A.

N.A.

Continuation of AA beyond progression (yes vs no)

N.A.

N.A.

N.A.

0.9863

0.992

0.382–2.574

N.A.

N.A.

N.A.

N.A.

N.A.

N.A.

Post-AA treatment (yes vs no)

N.A.

N.A.

N.A.

0.3604

0.51

0.117–2.219

N.A.

N.A.

N.A.

N.A.

N.A.

N.A.

  1. Abbreviations: HR hazard ratio, 95 % CI 95 % confidence interval, ADT androgen deprivation treatment, CRPC castration-resistant prostate cancer, ECOG Eastern Cooperative Oncology Group, Symptomatic presence of pain prior abiraterone acetate and require WHO level II or above analgesics, PSA prostate-specific antigen, ALP alkaline phosphatase, Hb haemoglobin, PSA response, ≥50 % drop of PSA from baseline, PSA flare, PSA upsurge but not to the extent of biochemical progression, AA abiraterone acetate, N.A. not applicable
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us